Detection of CBFbeta/MYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics

Leukemia
R CostelloJ Gabert

Abstract

Pericentric inversion of chromosome 16, translocation (16;16) and del(16q), resulting in a chimerical fusion of CBFbeta and MYH11 genes, are typically seen in the M4Eo French-American-British (FAB) classification subset of acute myelogenous leukemia (AML). In this study, we analyzed 70 cases of acute non-lymphoblastic leukemia, mainly of the M4 or M5 type. We report the very unusual presence of the t(16;16) and CBFbeta/MYH11 fusion transcript in an M7 patient. Ten M4Eo and four non-M4Eo patients presented an inv(16), t(16;16) or CBFbeta/MYH11 fusion transcript. In most cases, the common 'A-type' CBFbeta/MYH11 fusion transcript was detected. In addition to the eight different breakpoints and the three alternative splicing variants already described, evidence of a new CBFbeta/MYH11 fusion transcript was found which involves a 785-bp deletion of MYH11. Moreover, two patients had an unusual transcript, to our knowledge only observed once. Only one patient had abnormal eosinophilic differentiation without chromosome 16 cytogenetic abnormalities or detectable CBFbeta/MYH11 fusion. Conversely, only one patient presented CBFbeta/MYH11 fusion without abnormal eosinophilic differentiation. Altogether, our data suggest a correlation betwe...Continue Reading

Citations

Feb 3, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Sonya B ShahCarol L Shields
Nov 11, 1998·Cancer Genetics and Cytogenetics·M J MozziconacciM Lafage-Pochitaloff
May 5, 2000·The Biochemical Journal·B D Lichty, S Kamel-Reid
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Aug 28, 1998·Leukemia & Lymphoma·N AsouK Takatsuki
Nov 6, 2007·Cancer Genetics and Cytogenetics·Mar MalloFrancesc Solé
Jan 24, 2015·Molecular Cancer·John FischerNicoletta Sacchi
Nov 11, 1999·Oncogene·P L DavisJ R Marks
Oct 19, 2001·Oncogene·J DuysterS W Morris
Sep 15, 2017·Hematological Oncology·Nathalie Douet-GuilbertMarc De Braekeleer
Sep 20, 2002·Blood·James W VardimanRichard D Brunning

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Alternative splicing

Alternative splicing a regulated gene expression process that allows a single genetic sequence to code for multiple proteins. Here is that latest research.